BioMarin Pharmaceutical stock gains on Ascendis settlement and analyst upgrades

BioMarin Pharmaceutical stock (ISIN US09061G1013) is trading in the mid 60 dollar range as of September 3, 2026, with several recent developments including a global patent settlement with Ascendis Pharma and fresh analyst upgrades shaping the narrative for investors.

Ascendis settlement reshapes outlook

According to market coverage compiled on September 2, 2026, BioMarin Pharmaceutical Inc has entered binding terms with Ascendis Pharma to resolve global patent and ancillary disputes related to the growth hormone therapy branded Yuviwel, with BioMarin to receive a 20% royalty on net sales under the agreement.

Market commentary on the same day highlighted that this settlement removes a litigation overhang for the sector and positions BioMarin to benefit from future Yuviwel commercialization without bearing the associated development and marketing costs, which investors often view as a more capital efficient way to participate in a product’s revenue stream.

Analyst targets move higher

Fresh analyst activity has followed the settlement. As reported by a recent market data overview on September 2, 2026, Cantor Fitzgerald raised its price target for BioMarin from 85 USD to 86 USD while maintaining an Overweight rating, signaling a modest increase of 1 USD in expected value per share based on the firm’s model.

In parallel, Jefferies analyst Akash Tewari lifted his price target from 104 USD to 105 USD, also maintaining a Buy rating, which represents a further 1 USD upward adjustment in the firm’s projected fair value for the stock. This combination of targets in the mid 80s and low 100s underlines a view among covering analysts that BioMarin shares are undervalued relative to their fundamental prospects.

A separate valuation analysis published on September 3, 2026, described BioMarin Pharmaceutical Inc as potentially undervalued at a current price point of 66.97 USD, based on a comparison between that trading level and the firm’s intrinsic value estimates derived from cash flow and earnings projections. With the stock at 66.97 USD versus a 105 USD analyst target at Jefferies, the implied upside gap for that single assessment stands at 38.03 USD per share.

Share performance and market metrics

BioMarin stock opened at 66.97 USD in the most recent trading snapshot referenced by Empowered Funds LLC on September 3, 2026, indicating that institutional investors are actively building positions at this level.

The same commentary shows that, over the past 52 weeks, BioMarin shares have gained 11.7% while year to date the stock is up 11.1%, according to a comparative biotech performance overview dated September 2, 2026. These gains compare with stronger moves in some peers but still mark a double digit appreciation, confirming that the stock has participated in the broader biotech recovery while leaving scope for further catch up.

As of September 2, 2026, a Form 144 filing summarized by a secondary source reported that BioMarin had 193,573,759 common shares outstanding, providing a basis for market capitalization calculations. Using the 66.97 USD price as of September 3, 2026, this share count implies a market capitalization in the region of 12,956,000,000 USD, placing BioMarin firmly in the mid cap to lower large cap segment of the biotechnology sector.

The same Form 144 notice recorded a proposed insider sale of 17,557 common shares with an aggregate market value of 1,163,755.77 USD as of September 2, 2026, illustrating that individual executives are monetizing a small portion of their holdings, though the sale size remains negligible compared with the total shares outstanding.

Valuation focus for investors

The combination of a current trading price of 66.97 USD, double digit 11.1% year to date and 11.7% twelve month performance, and analyst targets between 86 USD and 105 USD frames valuation as a central consideration for investors evaluating BioMarin today.

Relative to the 86 USD target at Cantor Fitzgerald, the shares trade 19.03 USD below that level, while compared with the Jefferies 105 USD target, the gap is 38.03 USD. These quantified differences point to potential upside in the range of approximately 28.5% versus the lower target and 56.8% versus the higher target when computed from the 66.97 USD reference price, though actual returns will depend on future execution, regulatory outcomes and market conditions.

Sector comparison data dated September 2, 2026, noted that BioMarin’s 11.1% year to date gain lagged behind Vertex Pharmaceuticals, which had delivered a stronger performance over the same period, highlighting that some leading peers have already re-rated more aggressively. For investors, this contrast can be read as both a caution about relative momentum and an illustration of room for BioMarin to close part of the performance gap if upcoming catalysts land positively.

Upcoming conferences and investor communication

BioMarin announced on September 2, 2026 via its investor relations channel that it will participate in upcoming investor conferences, underlining management’s intent to communicate its growth story and recent strategic developments to the market.

Such conference appearances typically give the company an opportunity to reiterate guidance, provide updates on key clinical programs, and respond to investor questions about topics like the Ascendis settlement, Yuviwel royalty stream, and broader portfolio priorities. Investors often watch these events closely for subtle signaling on pipeline timelines and commercialization milestones that can influence valuation models.

Key products in rare disease

A central pillar of BioMarin’s business model is its focus on therapies for rare genetic diseases, where unmet medical need is high and pricing power often allows for attractive margins. One of the flagship products in this portfolio is the company’s enzyme replacement therapy for Morquio A syndrome, which has historically generated significant revenue due to its status as a primary treatment option for affected patients.

In addition, BioMarin has developed and commercialized therapies for conditions such as phenylketonuria, expanding its footprint across metabolic and inherited disorders. These niche indications typically have relatively small patient populations, but the chronic nature of treatment and the complexity of drug development can support durable revenue streams once products are established.

Stock level and investor perspective

Based on the latest market data snapshots dated September 3, 2026, BioMarin stock is trading around 66.97 USD on the NASDAQ, reflecting investor assessment of the companys rare disease portfolio, the newly agreed 20% Yuviwel royalty, and the risk adjusted value of its clinical pipeline.